P2Y4/TSP-1/TGF-β1/pSmad2/3 pathway contributes to acute generalized seizures induced by kainic acid.


Journal

Brain research bulletin
ISSN: 1873-2747
Titre abrégé: Brain Res Bull
Pays: United States
ID NLM: 7605818

Informations de publication

Date de publication:
07 2019
Historique:
received: 21 11 2018
revised: 07 03 2019
accepted: 08 04 2019
pubmed: 22 4 2019
medline: 21 7 2020
entrez: 22 4 2019
Statut: ppublish

Résumé

Epilepsy is accompanied by angiogenesis and blood-brain barrier (BBB) disruption. The transforming growth factor-β1 (TGF-β1)/phosphorylated small mothers against decapentaplegic 2 and 3 (pSmad2/3)/vascular endothelial growth factor (VEGF) pathway, activated by thrombospondin-1 (TSP-1), which is further regulated by Y type P2 purinergic receptor activity, may participate in angiogenesis. We sought to investigate the relationship between the P2R/TSP-1/TGF-β1/pSmad2/3/VEGF pathway, angiogenesis, and BBB damage in a kainic acid (KA) model of acute generalized seizure. Our results demonstrated that KA-induced seizures were accompanied by angiogenesis and BBB damage. In addition, expression of TSP-1, TGF-β1, and pSmad2/3 was increased. Rats treated with pyridoxal phosphate-6-azophenyl-2', 4'-disulfonic acid, a broad P2 receptor antagonist, or Reactive Blue 2, a potent P2Y4 receptor antagonist, showed significant attenuation of TSP-1 expression and Smad2/3 phosphorylation levels. Furthermore, angiogenesis, BBB damage, and acute seizure severity were also reduced. The inhibition of TSP-1 expression by siRNA or TGF-β1 activation by Leu-Ser-Lys-Leu (LSKL) treatment prevented KA-induced phosphorylation of Smad2/3, angiogenesis, BBB damage, and acute seizures. Our results strongly indicate that the P2Y4/TSP-1/TGF-β1/pSmad2/3/VEGF pathway plays an essential role in seizure pathophysiology and angiogenesis. Therapeutic interventions targeting this pathway may offer new treatment options for acute seizures.

Identifiants

pubmed: 31005663
pii: S0361-9230(18)30919-5
doi: 10.1016/j.brainresbull.2019.04.004
pii:
doi:

Substances chimiques

Angiogenesis Modulating Agents 0
Receptors, Purinergic P2 0
SMAD3 protein, human 0
Smad2 Protein 0
Smad2 protein, mouse 0
Smad3 Protein 0
Thrombospondin 1 0
Transforming Growth Factor beta1 0
Vascular Endothelial Growth Factor A 0
purinoceptor P2Y4 0
Thbs1 protein, mouse 0
Kainic Acid SIV03811UC

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-119

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Yurong Zhang (Y)

School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China.

Wei Zhu (W)

Shandong Academy of Medical Sciences, Jinan, China.

Haiying Yu (H)

Shandong Academy of Medical Sciences, Jinan, China.

Jie Yu (J)

School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China.

Mengdi Zhang (M)

School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China.

Xiaohong Pan (X)

School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China.

Xue Gao (X)

School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China.

Qiaoyun Wang (Q)

School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China.

Hongliu Sun (H)

School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China. Electronic address: sun_china6@163.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH